39 results on '"Vuppugalla, Ragini"'
Search Results
2. Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective
3. PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets
4. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution
5. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance
6. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach
7. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach
8. Rationale for the Clinical Use of Less Frequent Dosing of Mogamulizumab for T-Cell Lymphomas Using Population Pharmacokinetic and Exposure Response Analysis
9. BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
10. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport
11. Prospective Prediction of Plasma Pharmacokinetics of a Novel Immune-modulating Agent in Cancer Patients after Intra-tumoral Administration: Translation from Non-clinical Species to Humans
12. Quantification of human mAbs in mouse tissues using generic affinity enrichment procedures and LC–MS detection
13. Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2
14. Microsomal Cytochrome P450 Levels and Activities of Isolated Rat Livers Perfused with Albumin
15. Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective
16. Abstract 3760: Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade
17. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC–MS
18. Ultrasensitive Quantitative LC–MS/MS of an Inhibitor of Apoptosis Protein’s Antagonist in Plasma Using Protein Target Affinity Extraction
19. Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors
20. Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms
21. Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer
22. Discovery of Potent Heterodimeric Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Sustained Antitumor Activity
23. Effects of Nitric oxide on Cytochrome P450-mediated Drug Metabolism
24. Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19
25. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats
26. Abstract DDT01-03: Discovery of BMS-911543, a highly selective JAK2 inhibitor, as a clinical candidate for the treatment of myeloproliferative disease and other malignancies
27. Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2
28. PS3-21 Preclinical validation of CCR5 pharmacodynamic biomarkers
29. Evaluation of Cynomolgus Monkey Pregnane X Receptor, Primary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
30. Effect of Commonly Used Organic Solvents on the Kinetics of Cytochrome P450 2B6- and 2C8-Dependent Activity in Human Liver Microsomes
31. Route-dependent stereoselective pharmacokinetics of tramadol and its activeO-demethylated metabolite in rats
32. Discovery of Potent HeterodimericAntagonists of Inhibitorof Apoptosis Proteins (IAPs) with Sustained Antitumor Activity.
33. Hepatic Disposition of the Cytochrome P450 2E1 Marker Chlorzoxazone and its Hydroxylated Metabolite in Isolated Perfused Rat Livers
34. SELECTIVE EFFECTS OF NITRIC OXIDE ON THE DISPOSITION OF CHLORZOXAZONE AND DEXTROMETHORPHAN IN ISOLATED PERFUSED RAT LIVERS
35. ENZYME-SELECTIVE EFFECTS OF NITRIC OXIDE ON AFFINITY AND MAXIMUM VELOCITY OF VARIOUS RAT CYTOCHROMES P450
36. SHORT-TERM INHIBITORY EFFECTS OF NITRIC OXIDE ON CYTOCHROME P450-MEDIATED DRUG METABOLISM: TIME DEPENDENCY AND REVERSIBILITY PROFILES IN ISOLATED PERFUSED RAT LIVERS
37. Hepatic Disposition and Effects of Nitric Oxide Donors: Rapid and Concentration-Dependent Reduction in the Cytochrome P450-Mediated Drug Metabolism in Isolated Perfused Rat Livers
38. Evaluation of Cynomolgus Monkey Pregnane X Receptor, Primary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
39. Route‐dependent stereoselective pharmacokinetics of tramadol and its active O‐demethylated metabolite in rats
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.